Molecular classification of acute myeloid leukemia: are we there yet?

Editorial

Jerald P Radich. J Clin Oncol. 2008.

. 2008 Oct 1;26(28):4539-41.

doi: 10.1200/JCO.2008.16.4293. Epub 2008 Jun 16.

No abstract available

Comment on

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrózek K, Maharry K, Langer C, Baldus CD, Zhao W, Powell BL, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD. Paschka P, et al. J Clin Oncol. 2008 Oct 1;26(28):4595-602. doi: 10.1200/JCO.2007.15.2058. Epub 2008 Jun 16. J Clin Oncol. 2008. PMID: 18559874 Free PMC article.
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
Neubauer A, Maharry K, Mrózek K, Thiede C, Marcucci G, Paschka P, Mayer RJ, Larson RA, Liu ET, Bloomfield CD. Neubauer A, et al. J Clin Oncol. 2008 Oct 1;26(28):4603-9. doi: 10.1200/JCO.2007.14.0418. Epub 2008 Jun 16. J Clin Oncol. 2008. PMID: 18559876 Free PMC article. Clinical Trial.